Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 10:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 1,362 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: pump Clear all
Not yet recruiting Not applicable Interventional

Single Arm Intervention Trial of DEKA TWIIST TM Insulin Pump Utilizing Tidepool Loop Algorithm in Pregnant People With Pre-existing Type 1 Diabetes

NCT07808385
View directory record Official record
Conditions
Type 1 Diabetes, Pregnancy
Interventions
Automated Insulin Delivery (AID)
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Stanford, California • Aurora, Colorado • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 29, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

Perioperative Methadone Use to Decrease Opioid Requirement in Pediatric Spinal Fusion Patients

NCT02558010
View directory record Official record
Conditions
Scoliosis, Pain
Interventions
Methadone, Normal Saline, Morphine
Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
10 Years to 18 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 29, 2026, 10:58 AM EDT
Recruiting No phase listed Observational

Hepatic Artery Infusion Pump Chemotherapy for Liver Metastases From Resected Pancreatic and Duodenal Adenocarcinoma

NCT07845617
View directory record Official record
Conditions
Pancreas Cancer With Hepatic Metastase, Pancreas Adenocarcinoma, Duodenal Cancer, Duodenal Adenocarcinoma, Ampullary Adenocarcinoma
Interventions
Hepatic Artery Infusion Pump (HAIP), Floxuridine (FUDR)
Device · Drug
Lead sponsor
AdventHealth
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 29, 2026, 10:58 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Treatment of Children With Obstructive Sleep Apnea and Laryngomalacia: the Role of Laser Supraglottoplasty

NCT00394550
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Respiration Disorders
Interventions
supraglottoplasty with laser
Procedure
Lead sponsor
Indiana University
Other
Eligibility
1 Year to 18 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Oct 29, 2026, 10:58 AM EDT
Completed Not applicable Interventional Results available

Closed Loop Control in Adolescents Using Heart Rate as Exercise Indicator

NCT01945060
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
heart rate Control to Range System (hrCTR) using DiAs Platform, DiAs Control-to-Range System not informed for heart rate
Device · Other
Lead sponsor
Marc Breton
Other
Eligibility
12 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 29, 2026, 10:58 AM EDT
Completed Phase 4 Interventional Results available

Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris

NCT01951417
View directory record Official record
Conditions
Acne
Interventions
Adapalene/BPO Gel, Moisturizer SPF 30, Foam Wash
Drug · Other
Lead sponsor
Galderma R&D
Industry
Eligibility
9 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Boynton Beach, Florida • Nashville, Tennessee • Carrollton, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 29, 2026, 10:58 AM EDT
Completed Not applicable Interventional

A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Male Subjects With Hair Loss

NCT04450589
View directory record Official record
Conditions
Androgenetic Alopecia, Androgenic Alopecia, Telogen Effluvium, Thinning Hair, Hair Loss/Baldness, Hair Thinning
Interventions
ALRV5XR, ALRV5XR Shampoo, ALRV5XR Conditioner, ALRV5XR Hair Follicle Serum (Nutriment), Placebo, Placebo Shampoo, Placebo Conditioner, Placebo Hair Follicle Serum (Nutriment)
Dietary Supplement · Other
Lead sponsor
Arbor Life Labs
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Oct 29, 2026, 10:58 AM EDT
Completed Early Phase 1 Interventional

Effect of the InsuPatch on Automated Closed-loop Glucose Control in Type 1 Diabetes

NCT01787318
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
ePID closed loop system, InsuPatch
Device
Lead sponsor
Yale University
Other
Eligibility
12 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 29, 2026, 10:58 AM EDT
Completed Phase 1 Interventional

Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer

NCT02620800
View directory record Official record
Conditions
Metastatic Pancreas Adenocarcinoma
Interventions
5FU, nab-paclitaxel, bevacizumab, calcium leucovorin, oxaliplatin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
7
States / cities
Chicago, Illinois • Boston, Massachusetts • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Oct 29, 2026, 10:58 AM EDT
Terminated Not applicable Interventional Results available

Early Feasibility Study of Adaptive Advisory/Automated (AAA) Control of Type 1 Diabetes

NCT01939834
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Overnight CLC, Sensor-Augmented Pump Therapy (SAP)
Device
Lead sponsor
Sue Brown
Other
Eligibility
21 Years to 64 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 29, 2026, 10:58 AM EDT
Completed Phase 1 Interventional

Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes Mellitus Patients

NCT03436498
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin aspart SAR341402, Insulin aspart
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Little Rock, Arkansas • Denver, Colorado • West Des Moines, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 29, 2026, 10:58 AM EDT
Not yet recruiting Phase 1 Interventional

Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy

NCT07715903
View directory record Official record
Conditions
Colorectal Neoplasms, Neoplasms, Intrahepatic Cholangiocarcinoma, Adrenocortical Carcinoma, Metastasis, Neoplasm
Interventions
Carfilzomib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 29, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

Transversus Abdominis Plane Block in Microsurgical Breast Recon w/Abdominal Free Flap in Breast CA

NCT02601027
View directory record Official record
Conditions
Breast - Female
Interventions
Transversus Abdominis Plane (TAP) block, Nimbus Infusion Pump IV Administration, Bupivacaine infusion, Acetominophen, Hydromorphone, Oxycodone, Ondansetron
Procedure · Device · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Oct 29, 2026, 10:58 AM EDT
Withdrawn Phase 2 Interventional

Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer

NCT06518538
View directory record Official record
Conditions
Pancreatic Cancer Stage IV
Interventions
CPI-613, modified Folfirinox
Drug
Lead sponsor
Cornerstone Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 29, 2026, 10:58 AM EDT
Terminated Phase 2 Interventional Results available

The Effect of Pancreatic Polypeptide on Insulin Requirements for Type 1 & Post-pancreatectomy Diabetic Patients

NCT00791076
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Placebo, Pancreatic Polypeptide (PP)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 29, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver

NCT03366155
View directory record Official record
Conditions
Colorectal Cancer, Liver Metastases, Colorectal Adenocarcinoma, Colorectal Cancer With Hepatic Metastases, Colorectal Carcinoma
Interventions
Codman 3000 constant flow pump catheter, Panitumumab, FUDR-Dex, Oxaliplatin, 5FU, Irinotecan, HAIP installation, cetuximab, Medtronic SynchroMed II Pump, Floxuridine, Dexamethasone, EKG, CT C/A/P, CT Angiogram (abdomen), Tumor and normal liver biopsy, Leucovorin
Device · Drug · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 29, 2026, 10:58 AM EDT
Recruiting Phase 4 Interventional

Permissive Versus Strict Intrapartum Glucose Management in Type 1 Diabetes (PRISM-T1D)

NCT07293715
View directory record Official record
Conditions
Pregnancy, High Risk, Type 1 Diabetes
Interventions
Insulin, DEXCOM Continuous Glucose Monitor
Drug · Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 29, 2026, 10:58 AM EDT
Completed Phase 1 Interventional

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

NCT01176474
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
NY-ESO-1 157-165 (165V), Nivolumab, gp100:280-288 (288V), Montanide ISA 51 vegetable grade (VG), Ipilimumab, Apheresis Procedure
Biological · Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
16 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 29, 2026, 10:58 AM EDT
Not listed Phase 4 Interventional

The Efficacy and Safety of Faster Insulin Aspart (Fiasp®) Compared to Conventional Insulin Aspart (NovoLog®) as Correction Bolus

NCT04414579
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Faster Insulin Aspart (Fiasp®)
Drug
Lead sponsor
Mountain Diabetes and Endocrine Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Asheville, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Oct 29, 2026, 10:58 AM EDT
Completed Phase 3 Interventional

Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).

NCT00171483
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Tegaserod
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Timeline
2004 – 2005
U.S. locations
7
States / cities
Boynton Beach, Florida • Miami, Florida • Pembroke Pines, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2008 · Synced Oct 29, 2026, 10:58 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Prospective Study of Topical Vitamin C (THDA) Versus Topical Vitamin C (THDA) With Acetyl Zingerone

NCT05779280
View directory record Official record
Conditions
Wrinkle, Skin Pigmentation
Interventions
THDA + Acetyl Zingerone Topical Product, THDA
Other
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
30 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 29, 2026, 10:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fruquintinib Food Effect and Proton Pump Inhibitor Study

NCT04645940
View directory record Official record
Conditions
Drug Interaction, Food-drug Interaction
Interventions
fruquintinib with food/fruquintinib without food/fruquintinib with rabeprazole, fruquintinib without food/fruquintinib with food/fruquintinib with rabeprazole
Drug
Lead sponsor
Hutchison Medipharma Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 29, 2026, 10:58 AM EDT
Completed Not applicable Interventional

Model Predictive Control (MPC) Artificial Pancreas vs. Sensor Augmented Pump (SAP)/Predictive Low Glucose Suspend (PLGS) With Different Food Choices in the Outpatient Setting

NCT03767790
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
iAPS
Device
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Oct 29, 2026, 10:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Prophylactic Incisional Care in Obese Women at Cesarean

NCT02578745
View directory record Official record
Conditions
Wound Infections
Interventions
Prophylactic NPWT (PICO system), Standard Dressing
Device · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 29, 2026, 10:58 AM EDT